| Clarient Receives Patents for Taxane Biomarker (PR Newswire) Clarient, Inc. , a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that the United Kingdom Patent Office has granted a U.K. patent on the Company's TLE3 biomarker, a marker which may be used to predict which cancer patients will respond favorably to taxane therapy. Â In addition, the Company has received a Notice of Allowance from the United States Patent and Trademark Office for a U.S. patent on the TLE3 biomarker. Â Other patents for the TLE3 biomarker are pending in the U.S., Canada, Japan, China, India and elsewhere in Europe. us.rd.yahoo.com |
Intuitive Surgical: Robotic Heart Surgery Has Growing Pains Intuitive Surgical (ISRG) is the unchallenged global leader in the emerging field of minimally invasive robotic surgery. Over the last three years, Intuitive has one of the two best performing stocks of companies listed on the Nasdaq stock exchange with a market capitalization of at least $10 billion. Only the stock of the Chinese search engine Baidu (BIDU) has been able to match that performance. Over the last five years, the value of Intuitive stock has grown 563 percent. During this period, Apple (AAPL) has the only other Nasdaq-listed stock that has achieved this remarkable performance among companies worth over $10 billion.Complete Story » seekingalpha.com |
J&J Unit Recalls Hip Replacement Systems J&J's DePuy orthopedic-device unit is recalling hip replacement parts implanted in about 93,000 people world-wide because of the high rate of repeat surgeries needed. online.wsj.com |
Elan Critics to Depart Biotech Firm's Board Elan, the Irish biotech company locked in a spat with some of its shareholders and directors, said two critics on the board have decided to resign. online.wsj.com |
Abbott Laboratories Shares 'Marked Down' - Good Time to Buy? Roger I. McNamara submits: Over several decades a fixture in both its Industry and the larger market/economy, Abbott Labs (ABT) has been tagged with a share price markdown in recent weeks. From the low-mid 50's of not long ago it now struggles to hold onto $47, slightly over 5% atop its 52 week closing low but fully 17% beneath its 52 week best. Similarly as with both 50 and 200 day moving averages north of 50, the stock is now offered at noticeable discounts. What has brought this about, and what should the savvy investor do about it?Among the pharmaceutical entrants ABT has stood aside with a fairly low --- either side of 60% --- revenue component derived from prescription compounds, the remainder faithfully arriving through nutritional supplements and an assortment of diagnostic and testing devices aimed at vascular and other health shortcomings. Put another way, its product slate is comparatively diversified. It has nonetheless been widely noticed and documented that the company's pipeline of life-supporting medications had become weak, or, as one commentator cleverly put it, ABT was not delivering enough "shots on goal" toward the Food and Drug Administration's net minders, who in the meantime have grown more demanding and selective before escorting a new member through Phase III clinical trials. In addition to bolstering research and development outlays, Abbott's management elected to mobilize its fortress balance sheet, sporting $12.68 net current assets per share at year end 2009, toward buying its way to a prosperous future.Complete Story » seekingalpha.com |